High citation abstracts

11879110

Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution.
C Arden Pope, Richard T Burnett, Michael J Thun, Eugenia E Calle, Daniel Krewski, Kazuhiko Ito, George D Thurston
(Department of Economics, Brigham Young University, 142 FOB, Provo, UT 84602, USA. cap3@email.byu.edu)
JAMA

pollution health mortality health pollution exposure air_pollution mortality death ii mortality risk race diet alcohol_consumption risk air_pollution death mortality pollution mortality air_pollution mortality particle particles mortality exposure air_pollution risk mortality

11784875

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Joan H Schiller, David Harrington, Chandra P Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H Johnson
(University of Wisconsin Hospital and Clinics, Madison, USA.)
N. Engl. J. Med.

cisplatin paclitaxel patients patients regimen cisplatin paclitaxel cisplatin gemcitabine cisplatin docetaxel carboplatin paclitaxel patients percent months interval rate percent rate percent survival patients cisplatin paclitaxel treatment cisplatin gemcitabine disease treatment cisplatin paclitaxel grade renal toxicity percent patients vs percent cisplatin_plus paclitaxel patients had rate survival treatment

12748244

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Tomohide Tamura, Kazuhiko Nakagawa, Jean-Yves Douillard, Yutaka Nishiwaki, Johan Vansteenkiste, Shinzoh Kudoh, Danny Rischin, Richard Eek, Takeshi Hora ...
(Fourth Department of Internal Medicine, Kinki University School of Medicine, 377-2 Ohnohigashi Osakasayama, Osaka 589, Japan. mfukuoka@med.kindai.ac.jp)
J. Clin. Oncol.

doses patients nsclc patients advanced_nsclc platinum oral doses gefitinib groups tumor ci ci patients rates ci ci survival months median months symptom patients tumor response aes dose levels grade aes patients gefitinib gefitinib patients gefitinib had patients advanced_nsclc

15329413

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
William Pao, Vincent Miller, Maureen Zakowski, Jennifer Doherty, Katerina Politi, Inderpal Sarkaria, Bhuvanesh Singh, Robert Heelan, Valerie Rusch, Lucinda Fulton, Elaine Mardis, Doris Kupfer, Richard ...
(Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. paow@mskcc.org)
Proc. Natl. Acad. Sci. U.S.A.

egfr gene sensitivity cancers exon point_mutations codon exon tumors had alterations mutations tumors tumors had tumors tumors adenocarcinomas patients cigarettes smokers adenocarcinomas never_smokers tumors had mutations cancers current_smokers cells egfr wild-type protein mutant levels phosphorylation exon mutant concentrations drug adenocarcinomas never_smokers cancers mutations egfr gefitinib erlotinib sensitivity

15210113

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.
Jing Yang, Sendurai A Mani, Joana Liu Donaher, Sridhar Ramaswamy, Raphael A Itzykson, Christophe Come, Pierre Savagner, Inna Gitelman, Andrea Richardson, Robert A Weinberg
(Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA.)
Cell

metastasis cells primary tumors tumors metastasis breast tumor model metastasis expression cells loss activation induction cell_motility metastasis emt human breast cancers level expression invasive carcinoma tumor type loss e-cadherin expression emt tumor metastasis

15118073

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska, David N Louis, David ...
(Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA.)
N. Engl. J. Med.

patients response gefitinib egfr percent patients response sensitivity gefitinib mutations egfr gene primary tumors patients response gefitinib response had exposed gefitinib mutations after mutant proteins cells egfr gene patients patients response mutations mutations tumors patients primary exposed gefitinib percent mutations mutations patients activity response sensitivity inhibition gefitinib patients mutations egfr gene gefitinib mutations signaling screening mutations cancers patients response gefitinib

16014882

Erlotinib in previously treated non-small-cell lung cancer.
Frances A Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Koo ...
(Department of Medical Oncology, University Health Network, Princess Margaret Hospital Site, University of Toronto, Canada.)
N. Engl. J. Med.

erlotinib after failure second-line_chemotherapy patients had patients response chemotherapy therapy ratio oral erlotinib dose placebo patients randomization years percent had percent had platinum-based_chemotherapy percent erlotinib group percent response months months months months adjusted months months erlotinib percent patients erlotinib erlotinib survival patients after second-line_chemotherapy

16199517

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander, Jill P Mesirov
(Broad Institute of Massachusetts Institute of Technology and Harvard, 320 Charles Street, Cambridge, MA 02141, USA.)
Proc. Natl. Acad. Sci. U.S.A.

rna expression gene gene expression method gene groups genes data_sets leukemia survival method gene

15728811

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Susumu Kobayashi, Titus J Boggon, Tajhal Dayaram, Pasi A Jänne, Olivier Kocher, Matthew Meyerson, Bruce E Johnson, Michael J Eck, Daniel G Tenen, Balázs Halmos
(Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.)
N. Engl. J. Med.

mutations egfr gene specimens patients response egfr inhibitors inhibitors patients relapse egfr-mutant relapse after years treatment gefitinib dna egfr gene tumor relapse position egfr mutation gefitinib resistance

15766527

RAS is regulated by the let-7 microRNA family.
Steven M Johnson, Helge Grosshans, Jaclyn Shingara, Mike Byrom, Rich Jarvis, Angie Cheng, Emmanuel Labourier, Kristy L Reinert, David Brown, Frank J Slack
(Department of Molecular, Cellular and Developmental Biology, Yale University, P.O. Box 208103, New Haven, CT 06520, USA.)
Cell

cell loss utr expression cell degrees cell overexpression mutations human ras genes ras expression expression tumors normal tissue ras protein tumors

17167137

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson
(Vanderbilt University, Nashville, TN, USA. sandler@vanderbilt.edu)
N. Engl. J. Med.

patients cancers ecog patients recurrent chemotherapy paclitaxel carboplatin alone paclitaxel bevacizumab chemotherapy weeks bevacizumab weeks patients tumors brain_metastases hemoptysis status months group chemotherapy months group death survival months rates bleeding group bevacizumab carboplatin treatment patients survival risk

17625570

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka, Masashi Bando, Shoji Ohn ...
(Division of Functional Genomics, Jichi Medical University, Tochigi 329-0498, Japan.)
Nature

gene gene nsclc cells mouse human fusion transformed foci tumours out nsclc patients individuals mutations gene nsclc patients fusion kinase nsclc

17463250

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Takayuki Kosaka, Al ...
(Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.)
Science

egfr gefitinib erlotinib cancers egfr tumors cell_line resistance gefitinib inhibition met signaling cells sensitivity gefitinib specimens had resistance gefitinib erlotinib amplification met gefitinib resistance activation receptors cancers

19692680

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji ...
(State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong. tony@clo.cuhk.edu.hk)
N. Engl. J. Med.

gefitinib patients phase patients pulmonary adenocarcinoma nonsmokers per_day patients carboplatin dose patients rates gefitinib met primary gefitinib death ci patients positive gene egfr_mutation gefitinib death ci patients mutation death gefitinib ci rash patients gefitinib group group gefitinib treatment pulmonary adenocarcinoma tumor mutation egfr gene gefitinib

20573926

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Harut ...
(Miyagi Cancer Center, Miyagi, Japan.)
N. Engl. J. Med.

mutations egfr gefitinib chemotherapy patients metastatic egfr_mutations chemotherapy gefitinib patients gefitinib group group death gefitinib gefitinib group had survival months vs months chemotherapy group vs median months gefitinib group months chemotherapy group gefitinib group rash levels chemotherapy group gefitinib interstitial disease gefitinib patients egfr_mutations chemotherapy

20979469

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa, Marileila Varella-Garcia, Woo-Ho Kim, Thomas J ...
(Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. ekwak@partners.org)
N. Engl. J. Med.

cancers tumors alk tumors trial alk after screening tumor samples patients alk_rearrangements patients disease patients had treatment patients cohort after phase had crizotinib dose daily patients response therapy patients alk_rearrangements patients had exposure tobacco had adenocarcinomas mean treatment months patients patients disease patients crizotinib probability survival median drug grade inhibition alk tumors alk_rearrangement patients

22658128

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi, Henry C Pitot, Omid Hamid, Shailender Bhatia, R ...
(Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.)
N. Engl. J. Med.

death protein receptor ligands tumor cells system trial antibody patients cancers antibody days cycles had melanoma colorectal ovarian pancreatic gastric breast antibody therapy weeks range grade treatment patients patients response patients melanoma ovarian patients tumor rate disease rates weeks patients cancers melanoma

22658127

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins, Philip D Leming, Davi ...
(Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA. stopali1@jhmi.edu)
N. Engl. J. Med.

death receptor cells immune resistance antibody patients melanoma colorectal antibody dose response after treatment cycle patients cycles patients treatment grade patients deaths pulmonary toxicity dose patients response melanoma doses patients patients patients melanoma patients patients patients patients intratumoral expression pathway pretreatment tumor patients patients tumors had patients tumors had antibody patients melanoma tumor cells